Guideline-Directed Heart Failure Therapy Should Be Initiated at LVEF ≤40%
Initiate full guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) when left ventricular ejection fraction is ≤40%. 1, 2
EF-Based Treatment Thresholds
The 2022 AHA/ACC/HFSA guidelines establish clear LVEF cutoffs that determine treatment intensity 1, 2:
HFrEF (LVEF ≤40%): Full GDMT Required
This is the primary threshold where comprehensive disease-modifying therapy is mandatory. Patients require:
- Foundational therapy: Beta-blocker PLUS one of ARNI/ACE inhibitor/ARB
- Add mineralocorticoid receptor antagonist (MRA) for persistent symptoms
- SGLT2 inhibitor regardless of diabetes status
- Additional agents (ivabradine, hydralazine-isosorbide dinitrate) in specific circumstances 3
HFmrEF (LVEF 41-49%): GDMT Should Be Considered
The mildly reduced EF category represents a gray zone where evidence supports treatment benefit. Recent data demonstrates that GDMT produces mortality reduction in HFmrEF similar to HFrEF, with each mg equivalent of bisoprolol (HR 0.95, p=0.047) and ramipril (HR 0.95, p=0.044) showing incremental mortality benefit 4. Treat these patients with the same GDMT as HFrEF 1, 2.
HFpEF (LVEF ≥50%): Different Treatment Paradigm
Preserved EF requires evidence of elevated filling pressures (elevated natriuretic peptides, E/e' ≥15, or invasive hemodynamics) for diagnosis 1, 2. GDMT shows no mortality benefit in this population 4.
Critical Clinical Caveat: EF Trajectory Matters More Than Single Measurement
A crucial pitfall: LVEF has substantial within-person variability (SD 7.4%) and follows a normal distribution 5. Patients classified as HFmrEF have <25% probability of remaining in that category one year later 5. This variability creates risk for treatment underutilization.
HFimpEF (Improved EF): Continue Full GDMT
If a patient's LVEF improves from ≤40% to >40%, they are classified as HFimpEF and must continue full HFrEF treatment indefinitely 1, 2. This is non-negotiable because:
- EF can decrease after medication withdrawal in most patients 1
- Structural abnormalities (LV dilatation, diastolic dysfunction) persist despite EF improvement 1
- Changes in LVEF are not unidirectional 1
Practical Implementation Algorithm
At diagnosis:
- Measure LVEF by echocardiography
- If LVEF ≤40%: Immediately initiate GDMT (unless specific contraindications exist)
- If LVEF 41-49%: Initiate GDMT given mortality benefit 4
- If LVEF ≥50%: Confirm elevated filling pressures before HFpEF diagnosis; different treatment approach
During follow-up:
- Serial LVEF measurements will show variability—do not discontinue GDMT based on improved EF
- If EF improves to >40%, continue all HFrEF medications 1, 2
- Recognize that the HFmrEF category is particularly unstable 5
Real-World Implementation Gap
Despite clear guidelines, implementation remains suboptimal. Even in hospitalized HFrEF patients, only 77% receive triple therapy (RASI+beta-blocker+MRA) and 11% receive quadruple therapy at discharge 6. In the first 3 months after HFrEF diagnosis, only 9.8% receive ARNI, 35% receive MRA, and 26% receive SGLT2i 7. These therapies should be initiated immediately upon diagnosis, not gradually over months.
Bottom Line Treatment Threshold
Begin comprehensive GDMT at LVEF ≤40%, strongly consider it for LVEF 41-49%, and never discontinue it if EF improves above 40%. The traditional 40% cutoff remains the definitive threshold for mandatory treatment, but emerging evidence supports extending full therapy to the 41-49% range given similar mortality benefits and the inherent variability of EF measurements 1, 4, 5.